Zhifei Biotech’s bivalent dysentery vaccine is ready to start enrolling subjects
April 11, 2025
Source: drugdu
57
On April 8, Zhifei Biotech (300122) issued an announcement that it was recently learned that the bivalent dysentery conjugate vaccine developed by the company's wholly-owned subsidiary Zhifei Green Bamboo has obtained the Phase III clinical trial approval from the Bangladesh Drug Administration and is ready to start enrolling subjects.
The vaccine is designed to prevent bacterial dysentery caused by Shigella flexneri and Shigella sonnei, which affects 164.7 million people worldwide each year, especially in developing countries and children under 5 years old.
In the first three quarters of 2024, Zhifei Biotech achieved revenue of 22.786 billion yuan and net profit attributable to the parent of 2.151 billion yuan.
https://finance.eastmoney.com/a/202504083369655980.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Midea Group established the Medical Division and released Midea Medical’s annual new products April 14, 2025
- Operating income of 3.07 billion yuan in 2024, a year-on-year increase of 13.32% April 14, 2025
- CanSino Biologics and Jiankai Technology have a strategic partnership to explore new mRNA vaccine tumor immunity solutions April 14, 2025
- Products will not be easily replaced, and the impact of tariffs is limited. April 14, 2025
- The United States may impose tariffs on drug imports. Many pharmaceutical companies responded with “close attention” April 11, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
